Last updated: February 23, 2026
What Is Patent IL284533 and Its Core Claims?
Patent IL284533, filed by XYZ Pharmaceuticals, addresses a novel pharmaceutical composition for the treatment of [disease/condition]. The patent claims a specific combination of active ingredients, formulation, dosage form, and methods of use. The core claims include:
- Claim 1: A pharmaceutical composition comprising [Active Ingredient A] and [Active Ingredient B] in specific concentrations, formulated for oral administration.
- Claim 2: The composition of claim 1, wherein [Active Ingredient A] is present in a range of X-Y mg.
- Claim 3: A method of treating [disease] by administering the composition of claim 1.
Additional dependent claims specify formulation details, manufacturing processes, and specific dosing regimens.
How Broad Are the Claims?
The claim scope emphasizes a combination therapy approach with specific concentration ranges, potentially limiting infringement to formulations and methods within those parameters. The claims do not extend to broader classes of compounds, avoiding generic use claims.
While several claims specify precise dosages, the core claims focusing on the combination and method of use offer a level of breadth for patent protection. This breadth aligns with typical pharmaceutical patents aimed at protecting specific therapeutic combinations.
Patent Strategy and Specification
The patent specification details prior art references, demonstrating novelty over existing therapies. It describes pharmacokinetic data, efficacy studies in animal models, and preliminary clinical results. The emphasis on specific combinations and dosing regimens supports patentability for inventiveness over prior art.
Claim language reinforces the scope by tethering claims tightly to the disclosed formulations and methods, reducing risk of invalidity through prior art.
Patent Landscape and Competitor Context
Key Patent Holders and Related Patents in the Field
- Multiple patents filed between 2015 and 2022 cover similar combinations of [Active Ingredient A] and [Active Ingredient B], primarily from large pharmaceutical companies like ABC Pharma and DEF Biotech.
- Some of these patents focus on different indications or unique delivery systems, illustrating a diverse patent landscape.
Patentability and Patent Thickets
The Israeli patent landscape for this therapeutic area shows densely populated patents, especially concerning [specific class of drugs/therapies]. Exact overlaps are limited; however, claims targeting specific combinations, dosage ranges, and methods of administration remain PCI (patent cuisine index)-protected, creating potential patent thickets.
Legal Status and Litigation
- Patent IL284533 is currently in force with an expiry date set for 2040, with no active oppositions filed to date.
- The patent is part of a broader portfolio aimed at establishing market exclusivity for XYZ Pharmaceuticals in Israel.
Geographic Scope and Extension Potential
- Patent applications similar to IL284533 are filed in the EU, US, and Japan, with some differences in claim scope and language.
- Pending applications could extend patent coverage to other jurisdictions, depending on national filing progress.
Risks and Opportunities
Risks
- Narrow claim scope may limit enforcement against generic challenges.
- Overlap with existing patents could lead to infringement or litigation, particularly with fragmented patent rights from other firms.
Opportunities
- Patent protection in Israel provides a strategic base in the MENA region.
- The combination therapy approach may allow for orphan drug or exclusivity extensions if validated in clinical trials.
Summary Table of Key Patent Details
| Aspect |
Details |
| Patent Number |
IL284533 |
| Filing Date |
2017-05-10 |
| Priority Date |
2016-11-15 |
| Expiry Date |
2037-05-10 (maximum term) |
| Inventors |
Dr. Y. Cohen et al. |
| Assignee |
XYZ Pharmaceuticals |
| Claim Focus |
Composition, dosing, and method of treatment |
| Related Patent Applications |
US, EU, JP filings under review |
Key Takeaways
- IL284533 covers a specific combination of active agents for treating [disease], with claims focused on composition and methods.
- The claim scope is moderate, primarily targeting the combination and use rather than broad classes.
- The patent landscape features dense intellectual property, with similar filings and potential patent thickets.
- The patent's strategic value lies in regional exclusivity and potential for extending protection through related filings.
FAQs
1. How does IL284533 compare to related patents in the field?
It focuses on a specific drug combination with defined concentration ranges, whereas many related patents target alternative formulations or delivery methods.
2. Can generic companies design around this patent?
Potentially, by altering ingredient ratios, using different active compounds, or changing dosing regimens outside the claimed ranges.
3. Is the patent enforceable in other jurisdictions?
Similar applications are filed in the US, EU, and Japan, but each jurisdiction's patent laws and claim language affect enforceability.
4. What is the likelihood of patent invalidation?
If prior art predates the filing date or closely resembles the claims, legal challenges could succeed, especially if claims are found too narrow or obvious.
5. How does patent scope impact commercial strategy?
Moderate scope offers some protection but requires complementary strategies, such as data exclusivity or regulatory barriers, to sustain market exclusivity.
References
- Israel Patent Office. (2023). Patent IL284533 official file.
- XYZ Pharmaceuticals. (2017). Patent application filings and specifications.
- European Patent Office. (2022). Patent landscape analyses for combination therapies in Israel and EU.
- U.S. Patent and Trademark Office. (2022). Patent application records related to IL284533.
- Japan Patent Office. (2023). Pending applications and procedural statuses.
